반응식
[N:1]1([CH2:6][CH2:7][N:8]2[C:16]3[C:11](=[CH:12][C:13]([NH2:17])=[CH:14][CH:15]=3)[CH:10]=[N:9]2)[CH2:5][CH2:4][CH2:3][CH2:2]1.[Cl:18][C:19]1[CH:24]=[CH:23][C:22]([CH:25]2[CH2:30][CH2:29][CH:28]([C:31](O)=[O:32])[CH2:27][CH2:26]2)=[CH:21][CH:20]=1>>[Cl:18][C:19]1[CH:20]=[CH:21][C:22]([CH:25]2[CH2:26][CH2:27][CH:28]([C:31]([NH:17][C:13]3[CH:12]=[C:11]4[C:16](=[CH:15][CH:14]=3)[N:8]([CH2:7][CH2:6][N:1]3[CH2:5][CH2:4][CH2:3][CH2:2]3)[N:9]=[CH:10]4)=[O:32])[CH2:29][CH2:30]2)=[CH:23][CH:24]=1참가 물질
3
실험 절차
1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-ylamine and 4-(4-chloro-phenyl)-cyclohexanecarboxylic acid were processed as described in Example 17 to provide the title compound. MS (DCI/NH3) MS m/z 451 (M+H)+; 1H NMR (500 MHz, DMSO-d6) δ ppm 1.48 (m, 2 H), 1.64 (m, 2 H), 1.75–2.06 (m, 8 H), 2.42 (m, 1 H), 2.57 (m, 1 H), 3.03 (m, 2 H), 3.52 (m, 2 H), 3.71 (q, J=5.82 Hz, 2 H), 4.74 (t, J=6.24 Hz, 2 H), 7.29 (m, 2 H), 7.35 (m, 2 H), 7.55 (m, 1 H), 7.67 (m, 1 H), 8.13 (s, 1 H), 8.18 (s, 1 H), 9.69 (br s, N H).
출처 및 근거
- ORD 기록
- ord-3ef3fc7fddda436aac11ca8b93a4cf3d
- 출처 데이터셋
- uspto-grants-2006_07
- 특허 번호
- US07071182B2
연결된 노트
불러오는 중…